Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Baxter
Merck
Harvard Business School

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR FRAGMIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Fragmin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006083 ↗ Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed National Cancer Institute (NCI) Phase 3 2000-04-01 RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications. PURPOSE: Randomized phase III trial to determine the effectiveness of dalteparin in preventing catheter-related complications in cancer patients who are receiving chemotherapy through a catheter.
NCT00006083 ↗ Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed Upjohn Phase 3 2000-04-01 RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications. PURPOSE: Randomized phase III trial to determine the effectiveness of dalteparin in preventing catheter-related complications in cancer patients who are receiving chemotherapy through a catheter.
NCT00006083 ↗ Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed Jonsson Comprehensive Cancer Center Phase 3 2000-04-01 RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications. PURPOSE: Randomized phase III trial to determine the effectiveness of dalteparin in preventing catheter-related complications in cancer patients who are receiving chemotherapy through a catheter.
NCT00041782 ↗ Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients Terminated Brookdale University Hospital Medical Center Phase 2 2000-10-01 Study Plan: Adult cancer patients who have a low risk profile and present with DVT will receive dalteparin 200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU). Eligible patients who have signed the informed consent will be instructed on injection technique, will give themselves their first subcutaneous injection under supervision of the physician or the nurse and will be observed for a minimum of 1-2 hours prior to discharge. Patients may be admitted to an observation unit for up to 24 hours prior to discharge if medically necessary. Those patients without complications during the observation period will be given discharge instructions and an outpatient schedule to see one of the physician investigators daily for their subcutaneous injection of dalteparin, routine lab work and initiation of oral anticoagulation therapy. Patients that are proficient in administering their own injection with dalteparin will be evaluated every other day by the physician investigator. On days of home injection, the study nurse will call the patient to check on the patient's status and to remind the patient of his/her daily injection. Patients will undergo a physical examination every other day by the physician investigator directed towards the clinically affected areas until a therapeutic response (INR 2-3) on oral warfarin has been achieved or the patient's clinical condition warrants modification of therapy with or without hospitalization. Patients will remain on study for a minimum of 5 days with at least 1 day of therapeutic oral anticoagulation. The quality of life of the patients enrolled will be assessed by using the Modified Medical Outcome Study Short Form-20. An adapted version of the Rotterdam Symptom Checklist will be used to specifically assess patients with thrombosis. Patients will complete these two instruments at study entry, day 3, day 5 and at the end of study if different from day 5.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fragmin

Condition Name

Condition Name for Fragmin
Intervention Trials
Venous Thromboembolism 10
Pulmonary Embolism 4
Deep Venous Thrombosis 3
Thromboembolism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fragmin
Intervention Trials
Thromboembolism 19
Venous Thromboembolism 13
Thrombosis 11
Venous Thrombosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fragmin

Trials by Country

Trials by Country for Fragmin
Location Trials
United States 78
Canada 52
Russian Federation 8
Norway 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fragmin
Location Trials
Texas 7
California 5
New York 4
North Carolina 4
Missouri 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fragmin

Clinical Trial Phase

Clinical Trial Phase for Fragmin
Clinical Trial Phase Trials
Phase 4 9
Phase 3 11
Phase 2/Phase 3 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fragmin
Clinical Trial Phase Trials
Completed 23
Recruiting 4
Terminated 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fragmin

Sponsor Name

Sponsor Name for Fragmin
Sponsor Trials
Pfizer 12
Canadian Institutes of Health Research (CIHR) 5
Eisai Inc. 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fragmin
Sponsor Trials
Other 51
Industry 20
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School
Colorcon
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.